+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.

      Urologic Oncology

      therapeutic use, Aged, Taxoids, methods, Salvage Therapy, Retrospective Studies, mortality, drug therapy, blood, Prostatic Neoplasms, Prostate-Specific Antigen, adverse effects, administration & dosage, Paclitaxel, Orchiectomy, Middle Aged, Male, Kaplan-Meier Estimate, Humans, drug effects, Drug Resistance, Neoplasm, Disease-Free Survival, Carboplatin, Antineoplastic Combined Chemotherapy Protocols

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Docetaxel is considered first-line chemotherapy for patients with metastatic castrate resistant prostate cancer (CRPC). Carboplatin and paclitaxel have demonstrated activity in CRPC but published data are limited regarding use after docetaxel. A retrospective, bi-institutional review was conducted of patients with advanced CRPC treated with carboplatin plus paclitaxel after docetaxel. Therapy was evaluated for tolerability, response, and survival. Endpoints used modified Prostate Cancer Working Group 2 criteria. Twenty-five patients were identified from February 2000 to March 2008. Median pretreatment PSA was 130.2 ng/ml [range 0.1-2100]. Sites of metastases included bone (88%), lymph nodes (52%), pelvis (32%), lung (28%), and liver (20%). A median 4.5 cycles of docetaxel [range 1-22] were given with a median progression-free survival (PFS) of 12 weeks [range 2-68]. Eighty-eight percent of patients (22/25) were docetaxel-refractory at the initiation of therapy with carboplatin (AUC 4-6) day 1 plus paclitaxel 60-80 mg/m(2) days 1, 8, and 21 recycled every 28 days. Patients received a median of 3.5 cycles [range 1-8] of carboplatin/paclitaxel with a median PFS of 12 weeks [range 2-35]. Sixty-four percent of patients (16/25) achieved ≥ 30% reduction in PSA with a median overall survival of 42 weeks [95% CI 30.6-53.5 weeks]. Grade 3 or 4 adverse hematologic events occurred in 11/25 (44%) patients, with no neutropenic fever or grade 3/4 non-hematologic toxicity. Carboplatin/paclitaxel chemotherapy following docetaxel in metastatic CRPC is well tolerated with favorable PSA response rates and survival. This combination is a viable option after progression on docetaxel-based therapy. Copyright © 2011 Elsevier Inc. All rights reserved.

          Related collections

          Author and article information



          Comment on this article